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Abstract Middle ear carcinoid tumor (MEC T) is rare. Only 46 cases of MECT have been reported in the liter-
ature since the first case of MECT was described in 1980. We present here a case of primary MECT initially diag-
nosed as inflammatory aural polyp. The case was a 43-year-old women complaining of right ear chronic otorrhea
and hearing loss over a period of five years, with a blockage sensation in the right ear for two years. Audiometry
showed conductive hearing loss in the right ear. Physical examination and CT scans showed a mass in the right ex-
ternal auditory canal and middle ear, surrounding the ossicular chain. Pathologic study of surgically removed speci-
men revealed features of carcinoid tumor with positive staining to chromogranin A and synaptophysin in tumor
cells. Local radiation of 60 Gy was applied. The patient has been followed up for more than one year. Postopera-
tive histopathological examination showed no evidence of MECT recurrence one year after surgery, but inflamma-
tory changes in the middle ear. Relevant literatures were reviewed. Clinical, histopathological, immunohistochemi-
cal and ultrastructural features of MECT, and strategies in MECT diagnosis and management are discussed.
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Introduction
Middle ear carcinoid tumor(MECT) is a rare form
of neoplasm. Since the first case of MECT was report-
ed by Murphy et al. in 1980（Murphy et al, 1980）,
there have been only forty-six cases of MECT reported
in the literature (Ramsey et al, 2005), with only three
cases reported in China (Feng et al, 2001; Zhang et al,
2005; Chan et al, 2005). We present here a case of pri-
mary MECT, which was initially diagnosed as inflam-
matory aural polyp. The literature is reviewed. Clini-
cal, histopathological, immunohistochemical and ultra-
structural features of MECT, as well as strategies for di-
agnosis and management of MECT are discussed.
Case Report
A 43-year-old woman presented in November,
2004, with chronic otorrhea and hearing loss on the
right for five years, and a gradually increasing block-
age sensation for two years. Physical examination re-
vealed a soft tissue mass blocking the right external au-
ditory canal. Audiometry showed conductive hearing
loss in the affected ear. High-resolution CT scans
showed a soft-tissue density mass in the external canal
and in the middle ear on the right side, surrounding a
relatively intact ossicular chain, without mastoid in-
volvement (Figure 1). Biopsy of the external audi-
tory canal mass suggested inflammatory aural polyp.
The patient underwent resection of the external au-
ditory canal mass. The mass was found to have origi-
nated from the middle ear through a perforation in the
eardrum and was wrapped in a fibrous capsule. The le-
sion tissues were removed completely. Exploration of
the middle after removed all the lesion revealed an in-
tact ossicular chain. This was followed by a modified
tympanoplasty.
Examination of the specimen with H & E staining
demonstrated morphologic features of a carcinoid tu-
mor. Immunohistochemical examinations showed posi-
tive staining to chromogranin A and synaptophysin, but
not to S100, cytokeratin 20 and cytokeratin 7, in tumor
cells(Figure 2), A diagnosis of MECT was made based
upon these findings. Two weeks after the surgery, the
patient received local radiation with a total dose of 60
Gy. At the 1 year follow-up visit, CT scan suggested
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Figure 1． Axial CT scan showing the right middle ear.
A soft tissue density mass is seen in the right external audi-
tory canal and tympanic cavity. The mastoid remains well
pneumatized bilaterally.
possible recurrence of MECT in the middle ear. The
right middle ear was reopened and found where filled
with granulation tissues with signs of ossicular chain
erosion. After removed the lesion and the eroded ossi-
cles including malleus, incus and stapes cruses, a modi-
fied tympanoplasty was conducted to reconstruct hear-
ing. Histopathologic examination of the removed le-
sion showed no evidence of MECT recurrence, except
features of inflammatory tissues.
Discussion
Carcinoid tumors are neuroendocrine neoplasms.
They are relatively common in the digestive and respi-
ratory systems. Carcinoid tumors are extremely rare in
the middle ear (Soga, 2003). Only have 46 middle ear
cases been reported since MECT was first described by
Murphy et al. in 1980(Murphy et al, 1980; Ramsey et
al , 2005).
Histogenesis of MECT
Although carcinoid tumors are labeled as neuroen-
docrine tumors, they can also originate in tissue lack-
ing neuroendocrine cells, such as that in the middle
ear(Nikanne et al, 2004). The cell origin of MECT is
still speculative. MECT most likely originates from
pre-existing neuroendocrine cells or a primitive precur-
sor cell (Murphy et al, 1980).
Histologically, MECT exhibits both glandular and
neuroendocrine differentiation. Based on immunohisto-
chemistry and electron microscopy, three cell types
may be found in MECT. Most frequent are B cells with
an abundant pale cytoplasm containing neuroendocrine
granules. Less frequent are A cells, which are slender,
darkly staining and line the glandular lumina. Least fre-
quent are amphicrine cells, which are characterized by
both lumina and neuroendocrine granules in their cyto-
plasm and interpreted as the link between A and B
cells(Manni et al, 1992; Faverly et al, 1992). It is be-
lieved that MECT represents a distinct entity and can
be classified as adenocarcinoids or amphicrine tumors,
i.e. demonstrating both exocrine and endocrine activi-
ties (Faverly et al, 1992).
Clinical Features of MECT
Recently, Ramsey et al (2005). reviewed the litera-
ture to identify the clinical features of MECT. Symp-
toms of MECT are not characteristic. The most com-
mon presenting symptom is hearing loss (Ramsey et al,
2005; Manni et al, 1992). From a review of 30 reported
Figure 2. Sections of the tumor showing mixed solid tra-
becular and tubuloglandular structures consisten with fea-
tures of carcinoid tumor. Immunohistochemical stainning is
positive to chromogranin (A) and synaptophysin (B), ×400
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cases by Nyrop et al(1994), it seems that nearly all pa-
tients have progressive hearing loss, most often of the
conductive type, and that about half of the patients
complain of tinnitus and fullness of the ear. Systemic
symptoms including carcinoid syndrome are uncom-
mon(Ramsey et al, 2005; Nyrop et al 1994). On oto-
scopic examination, the eardrum is intact in most pa-
tients with MECT, and erythema or lateral bulging of
the tympanic membrane is seen commonly. A whitish
or reddish bulging mass can be observed through the
intact tympanic membrane. In some cases, the ear-
drums may be perforated (Nikanne et al, 2004; Manni
et al, 1992; Nyrop et al, 1994) The tumor is most often
localized to the middle ear with varying degree of ex-
tensions into neighboring areas(Nyrop et al, 1994). The
ossicular chain is often encased by the tumor, with or
without ossicle erosion(Manni et al, 1992; Nyrop et al,
1994). MECT may erode facial canal resulting in facial
palsy (Chan et al, 2005; Nikanne et al,2004).
Histopathology, immunohistochemistry and ultra⁃structure of MECT
Microscopically, MECT shows histologic features
of a carcinoid tumor, such as ribbon or festoon arrange-
ment of tumor cells, formation of anastomosing cords
and glandular spaces, presence of numerous argyrophil-
ic as well as argentaffin secretory granules within
many of the tumor cells. However, MECT shows a
striking, heterogeneous aspect. Both solid trabecular
and tubuloglandular growth patterns, resembling the
classic carcinoid tumor and adenomatous tumor respec-
tively, may be identified in MECT(Faverly et al, 1992).
MECT is typically keratin- and vimentin-positive
immunohistochemically. Neuroendocrine cell differen-
tiation, a carcinoid feature, may be demonstrated by
the presence of numerous argyrophil granules in
MECT cells. Immunohistochemically, the tumors are
found to contain not only neuronal marker substances
such as neuron-specific enolase, S-100 protein, synap-
tophysin, and chromogranin A, but also serotonin and
multiple peptide hormones such as pancreatic polypep-
tide, glucagon, cholecystokinin and leucine-enkephalin
(Nikanne et al, 2004; Mandigers et al, 1996; Devaney,
et al, 2003). Dense intracellular neurosecretory gran-
ules may be identifiable by electron microscopy (Ni-
kanne, et al, 2004; Devaney et al, 2003).
Diagnosis and Differentiation Diagnosis of MECT
Diagnosis of MECT is difficult since the tumors
grow slowly and produce non-specific symptoms, easi-
ly leading to a relatively late diagnosis (Nikanne et al,
2004; Riddell et al, 1994). In many cases, primary
MECT are identified by postoperative histological ex-
aminations. It is almost impossible to diagnose MECT
solely based upon light microscopy. MECT should be
considered in differential diagnosis when biologically
low-grade tumors with glandular and trabecular archi-
tectures are encountered in the middle ear (Murphy et
al, 1980). Diagnostic precision has increasingly im-
proved over the years owing to the use of modern im-
munohistochemical techniques and electron microsco-
py, which are necessary for a definite diagnosis of
MECT(Nyrop et al, 1994).
Primary MECT are very difficult to distinguish
from adenomas and adenocarcinomas using convention-
al histological stains. There are some differences but al-
so some similarities between carcinoid tumors and ade-
nomas of the middle ear(Murphy et al, 1980). Both of
them share a sufficient number of overlapping patholog-
ic features and similarities of clinical behavior to war-
rant their collapse into a single diagnostic category
(Chan et al, 2005; Devaney et al, 2003). Also MECT
may commonly be mistaken for an adenocarcinoma be-
cause of its histological heterogeneity. The diagnosis of
carcinoid tumor should be considered in all cases of ad-
enomatous neoplasm of the middle ear and mastoid
(Krouse et al, 1990). Additionally, there is a strong clini-
cal and endocrinological resemblance between MECT
and functioning paragangliomas. As distinction from
the more common paraganglioma may be difficult on
morphologic grounds alone, immunohistochemical
studies should be performed (Mandigers et al, 1996;
Menezes et al, 2001). Immunohistochemical and elec-
tron microscopic studies are of great value in distin-
guishing carcinoid from other tumors of the middle
ear(Riddell et al, 1994 ).
Treatment and prognosis of MECT
A broad range of diverse therapeutic measures
have been employed in the reported cases of MECT.
The tumor is primarily treated surgically and radical
mastoidectomy is the most common procedure
(Ramsey et al, 2005; Nikanne et al, 2004). Surgical
treatment should be tailored to the extent of disease
(Ramsey et al, 2005). MECT, a low-grade malignant tu-
mor histologically, is clinically benign and total exci-
sion of the tumor and affected ossicles is an adequate
treatment (Nyrop et al, 1994; Krouse et al, 1990). A
conservative surgery with complete removal of the pri-
mary or recurrent tumor appears also to be the treat-
ment of choice for MECT, but clinical follow-up on a
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regular basis is recommended(Manni et al, 1992; Dev-
aney et al, 2003; Riddell et al, 1994). As MECT is very
rare, there is no statistical evidence as to whether fur-
ther treatment is necessary after surgical resection of
the tumor. However, it has been reported that addition-
al radiotherapy was applied to MECT after surgery
(Krouse et al, 1990; Kodama et al, 1989).
In general, the prognosis of MECT is excellent
with radical excisions from middle ear. Local recur-
rence following complete excision is quite uncommon
(Menezes et al, 2001). Successful treatment of MECT
requires complete excision of the tumor mass, along
with the ossicles if they are involved with disease, in
order to prevent local recurrence(Krouse et al, 1990).
However, local recurrence of a primary MECT 15
years after radical tympanomastoidectomy has been re-
ported, indicating that primary MECT can recur years
after radical tympanomastoidectomy(Knerer et al,
1998). But local recurrence of MECT may still be treat-
ed successfully with surgery(Manni et al, 1990).
MECT may metastasize to cervical lymph nodes al-
though with a low metastasize rate (Mooney et al,
1990). These tumors also have a low propensity for dis-
tant metastasis(Krouse et al, 1990). One case of meta-
static disease has been reported, thus MECT has a low
but definite metastatic potential(Mandigers et al, 1996).
MECTs show benign behaviors and most of them
have an indolent biological course, with little destruc-
tion of surrounding tissues, therefore, some authors be-
lieve that MECT is a rare benign tumor(Nyrop et al,
1994; Devaney et al, 2003). A recent review of the liter-
atures has shown that in the 46 reported cases, 10
(22%) patients developed locally recurrent disease, and
four (9% ) developed regional metastases (Ramsey et
al, 2005). Despite previous assertions of benignancy,
those studies suggested that MECT is indeed a poten-
tial low-grade malignancy with documented metastatic
potential. Patients with MECT require indefinite fol-
low-up for possible recurrence or metastasis (Ramsey
et al, 2005). In the follow-up of patients, octreotide
scanning has proved to be a sensitive method in cases
of both recurrence and metastasis (Nikanne et al, 2004).
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